

Fabio S Macaluso

List of Publications by Citations

Source: <https://exaly.com/author-pdf/61380/fabio-s-macaluso-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

86

papers

1,424

citations

20

h-index

34

g-index

92

ext. papers

1,785

ext. citations

4.7

avg, IF

4.87

L-index

#	Paper	IF	Citations
86	Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. <i>Gastroenterology</i> , 2016 , 150, 145-155.e4; quiz e15-6	13.3	156
85	The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015 , 62, 1101-10	11.2	131
84	Screening of colorectal cancer: present and future. <i>Expert Review of Anticancer Therapy</i> , 2017 , 17, 1131-1146	11.4	74
83	Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2014 , 59, 1692-705	11.2	64
82	Cardiovascular diseases and HCV infection: a simple association or more?. <i>Gut</i> , 2014 , 63, 369-75	19.2	60
81	Genetic background in nonalcoholic fatty liver disease: A comprehensive review. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11088-111	5.6	59
80	Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. <i>Liver International</i> , 2011 , 31, 507-15	7.9	58
79	Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014 , 61, 523-9	13.4	57
78	Herbal hepatotoxicity: a hidden epidemic. <i>Internal and Emergency Medicine</i> , 2013 , 8, 13-22	3.7	43
77	Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 486-93	3.4	42
76	Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, e31	2.4	29
75	Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. <i>Digestive and Liver Disease</i> , 2014 , 46, 1116-20	3.3	28
74	Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2013 , 59, 1169-76	13.4	28
73	COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data. <i>Digestive and Liver Disease</i> , 2020 , 52, 1222-1227	3.3	26
72	Serum Eglutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. <i>PLoS ONE</i> , 2012 , 7, e51165	3.7	24
71	Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease. <i>Journal of Infection</i> , 2017 , 74, 433-441	18.9	23
70	Metabolic factors and chronic hepatitis C: a complex interplay. <i>BioMed Research International</i> , 2013 , 2013, 564645	3	23

69	Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 89-98	5.4	23
68	The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. <i>Digestive and Liver Disease</i> , 2018 , 50, 675-681	3.3	22
67	The hepatic expression of vitamin D receptor is inversely associated with the severity of liver damage in genotype 1 chronic hepatitis C patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 193-200	5.6	21
66	Psoriasis and Inflammatory Bowel Disease. <i>Digestive Diseases</i> , 2019 , 37, 451-457	3.2	19
65	Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 1805-1812	4.5	19
64	A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor- α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, 209-217	1.5	19
63	The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 182-189	4.5	19
62	Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. <i>World Journal of Hepatology</i> , 2013 , 5, 685-91	3.4	18
61	PNPLA3 rs738409 T748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 939-48	6.1	16
60	Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 193-203	5.4	16
59	Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. <i>Scandinavian Journal of Gastroenterology</i> , 2017 , 52, 981-987	2.4	15
58	Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. <i>Liver International</i> , 2012 , 32, 1443-50	7.9	15
57	Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014 , 46, 936-42	3.3	14
56	Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature. <i>Current Molecular Medicine</i> , 2016 , 16, 721-737	2.5	12
55	Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). <i>Drugs and Aging</i> , 2020 , 37, 383-392	4.7	12
54	TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. <i>Liver International</i> , 2016 , 36, 198-204	7.9	12
53	Is Epstein-Barr virus infection associated with the pathogenesis of microscopic colitis?. <i>Journal of Clinical Virology</i> , 2017 , 97, 1-3	14.5	11
52	A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. <i>Digestive and Liver Disease</i> , 2018 , 50, 1292-1298	3.3	11

51	High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 174-82	3.4	10
50	Body mass index and liver stiffness affect accuracy of ultrasonography in detecting steatosis in patients with chronic hepatitis C virus genotype 1 infection. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 878-884.e1	6.9	10
49	Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 987-997	4.5	10
48	The Addition of an Immunosuppressant After Loss of Response to Anti-TNF Monotherapy in Inflammatory Bowel Disease: A 2-Year Study. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 394-401	4.5	9
47	Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. <i>Digestive and Liver Disease</i> , 2019 , 51, 613-620	3.3	8
46	Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study. <i>United European Gastroenterology Journal</i> , 2020 , 8, 1045-1055	5.3	8
45	Letter: SPOSIB SB2-a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 234-236	6.1	8
44	Physicians Knowledge and Application of Immunization Strategies in Patients with Inflammatory Bowel Disease: A Survey of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestion</i> , 2020 , 101, 433-440	3.6	8
43	The Selective Use of Combination Therapy in Patients with Inflammatory Bowel Disease Resistant to Anti-TNF: to Whom, How and How Long?. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 1451	1.5	7
42	Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 310-1	6.1	7
41	A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 105-111	4	7
40	Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases. <i>JGH Open</i> , 2021 , 5, 364-370	1.8	7
39	The biologics of ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 175-184	5.4	6
38	Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are insidious adverse events: data from a large single-center cohort. <i>Scandinavian Journal of Gastroenterology</i> , 2019 , 54, 1102-1106	2.4	6
37	Frequency of thiopurine methyltransferase mutation in patients of Mediterranean area with inflammatory bowel disease and autoimmune disorders. <i>Digestive and Liver Disease</i> , 2016 , 48, 1506-1509	3.3	6
36	Risk of Pneumonia Caused by <i>Pneumocystis jirovecii</i> in Inflammatory Bowel Disease: The Role of Concomitant Pulmonary Comorbidities. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 571-572	6.9	6
35	Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?. <i>Gastroenterology</i> , 2021 , 160, 1877-1878	13.3	6
34	A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis. <i>Digestive and Liver Disease</i> , 2020 , 52, 1461-1466	3.3	5

33	Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1040-1041	6.1	5
32	The METEOR Trial: The Burial of Methotrexate in Ulcerative Colitis?. <i>Gastroenterology</i> , 2016 , 151, 211-2	13.3	5
31	Hepatocellular carcinoma and synchronous liver metastases from colorectal cancer in cirrhosis: A case report. <i>World Journal of Hepatology</i> , 2013 , 5, 696-700	3.4	5
30	Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2020 , 52, 1304-1309	3.3	5
29	Prevalence and incidence of inflammatory bowel disease in two Italian islands, Sicily and Sardinia: A report based on health information systems. <i>Digestive and Liver Disease</i> , 2019 , 51, 1270-1274	3.3	4
28	AISF position paper on HCV in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2019 , 51, 10-23	3.3	4
27	Antimitochondrial antibody -M2 positive autoimmune hepatitis during standard of care for chronic hepatitis C. <i>Hepatology Research</i> , 2012 , 42, 428-32	5.1	3
26	Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF- α inhibitors and conventional immunosuppressants. <i>Digestive and Liver Disease</i> , 2017 , 49, 157-162	3.3	3
25	Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort. <i>Hepatitis Monthly</i> , 2016 , 16, e31681	1.8	3
24	Vaccinations in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2021 , 53, 1539-1545	3.5	3
23	Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients. <i>Infection</i> , 2019 , 47, 409-415	5.8	3
22	Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211010668	4.7	3
21	Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. <i>Future Microbiology</i> , 2015 , 10, 977-88	2.9	2
20	How clinicians and pathologists interact concerning inflammatory bowel disease in Italy: An IG-IBD survey. <i>Digestive and Liver Disease</i> , 2018 , 50, 734-736	3.3	2
19	Education and Imaging. Hepatobiliary and pancreatic: Portal hypertensive biliopathy presenting as acute cholangitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28, 1257	4	2
18	Ozanimod for Ulcerative Colitis.. <i>New England Journal of Medicine</i> , 2022 , 386, 194	59.2	2
17	Primary biliary cirrhosis and hereditary hemorrhagic telangiectasia: When two rare diseases coexist. <i>World Journal of Hepatology</i> , 2013 , 5, 288-91	3.4	2
16	Progressive multi-organ expression of immunoglobulin G4-related disease: A case report. <i>World Journal of Hepatology</i> , 2013 , 5, 336-9	3.4	2

15	Anti-TNF combination therapy in inflammatory bowel disease: de novo or selective?. <i>Minerva Gastroenterologica E Dietologica</i> , 2019 , 65, 291-297	1.6	2
14	Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthritis: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 1381-1384	5.4	2
13	A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence. <i>Expert Opinion on Biological Therapy</i> , 2021 ,	5.4	2
12	Letter: psoriasiform eruption during vedolizumab therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 342-343	6.1	1
11	JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease. <i>Current Drug Metabolism</i> , 2020 , 21, 247-255	3.5	1
10	SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 3041-3049	4	1
9	Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.. <i>Inflammatory Bowel Diseases</i> , 2022 ,	4.5	1
8	Letter: propensity score-handle with care. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 360-361	6.1	1
7	Herpes Zoster Eruption During Vedolizumab Therapy: A Simple Coincidence or More?. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, e51-e52	4.5	0
6	Letter: mesalazine-a safe drug with rare serious adverse events. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 1210-1211	6.1	0
5	The key role of colonoscopy at 6 months from ileocolonic resection in Crohn's disease patients. <i>Digestive and Liver Disease</i> , 2021 , 53, 517-518	3.3	0
4	Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 1019-20	6.1	0
3	Rescue Therapy with Intensive Vedolizumab Optimization in a Seventeen-Year-Old Girl with Acute Severe Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 2470-2471	4	0
2	Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IBD randomized double-blind trial. <i>European Review for Medical and Pharmacological Sciences</i> , 2020 , 24, 11356-11364	2.9	0
1	The VERSIFY Trial: What About Ultrasound Assessment?. <i>Gastroenterology</i> , 2020 , 158, 1176-1177	13.3	